Octreotide scintigraphy
Octreotide scintigraphy uses In-labeled octreotide which is a somatostatin analog; it is also known as an Octreoscan, a brand name for In-labeled pentetreotide; pentetreotide is a DTPA-conjugated form of octreotide, originally manufactured by Mallinckrodt Nuclear Medicine LLC, which now forms part of Curium).
The radiotracer is characterized by a high affinity of bond with the somatostatin receptor 2 (SST2). It penetrates inside the cell by endocytosis, first held by lysosomes and then transferred to the nucleus .
It is particularly useful for assessment of neuroendocrine tumors, and the Krenning Score is used to grade these, most commonly for peptide receptor radionuclide therapy (PRRT) planning.
Examples include:
- carcinoid tumor
- paraganglioma
- small cell lung cancer
- pituitary adenoma
- neuroblastoma
- medullary thyroid carcinoma
- pancreatic islet cell tumor
Certain non-neuroendocrine tumors can also show uptake in an octreoscan. Examples include:
Also, certain autoimmune or granulomatous diseases (for example sarcoidosis) may occasionally show octreotide uptake by overexpression of somatostatin receptors.
Siehe auch:
- Neuroblastom
- Glomus caroticum Tumor
- Karzinoid
- Astrozytom
- Paragangliom
- Glomus jugulare Tumor
- Phäochromozytom
- Hypophysenadenom
- neuroendokrine Pankreastumoren
- Neuroendokriner Tumor
- Medulläres Schilddrüsenkarzinom
- Kleinzelliges Lungenkarzinom
- Paragangliom des Nervus vagus
- Neoplasien der Mamma
und weiter:
Assoziationen und Differentialdiagnosen zu Somatostatin-Rezeptor-Szintigrafie:
